Anzeige
Mehr »
Login
Samstag, 06.03.2021 Börsentäglich über 12.000 News von 657 internationalen Medien
Bam Bam Resources und die Mega-Kupferlagerstätte in Teslas Hinterhof!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JP36 ISIN: SE0010441584 Ticker-Symbol: LC8 
Frankfurt
05.03.21
09:16 Uhr
11,460 Euro
-0,440
-3,70 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
CALLIDITAS THERAPEUTICS AB Chart 1 Jahr
5-Tage-Chart
CALLIDITAS THERAPEUTICS AB 5-Tage-Chart

Aktuelle News zur CALLIDITAS THERAPEUTICS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoCalliditas Therapeutics to Host Key Opinion Leader Perspectives Webinar on the Pathophysiology and Treatment of IgA Nephropathy in Clinical Practice104STOCKHOLM, March 4, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that it will host a Key Opinion Leader (KOL) Perspectives webinar on the Pathophysiology...
► Artikel lesen
CALLIDITAS THERAPEUTICS Aktie jetzt für 0€ handeln
18.02.Calliditas Therapeutics AB - 6-K, Report of foreign issuer-
18.02.Calliditas Therapeutics: Year-End Report, 2020339STOCKHOLM, Feb. 18, 2021 /PRNewswire/ -- "On November 8, 2020, we announced positive topline readout of Part A of our Phase 3 pivotal trial, NefIgArd. The results were statistically significant...
► Artikel lesen
04.02.Calliditas Starts Dosing In Nefecon Open Label Extension Study In Kidney Disease1
04.02.CALLIDITAS THERAPEUTICS: First Patient Dosed in NefIgArd Open Label Extension Study-
28.01.Calliditas halts proposed global offering1
28.01.Calliditas announces termination of the proposed global offering199STOCKHOLM, Jan. 28, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX; Nasdaq - CALT) today announced that despite significant interest, it will not...
► Artikel lesen
28.01.CALLIDITAS THERAPEUTICS: Calliditas announces termination of the proposed global offering3
27.01.Calliditas Therapeutics readies 4.5M shares offering-
26.01.Calliditas Therapeutics launches proposed global offering288STOCKHOLM, Jan. 26, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX: CALTX) (Nasdaq: CALT) will today launch a proposed public offering of American Depositary...
► Artikel lesen
26.01.Calliditas Therapeutics AB - F-1, Registration statement for certain foreign private issuers1
21.01.Calliditas completes enrollment in late-stage Nefecon trial-
21.01.Calliditas Announces Full Enrollment of the Phase 3 NefIgArd Trial292STOCKHOLM, Jan. 21, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX: CALTX) (NASDAQ: CALT) today announced that all 360 patients have been enrolled for the...
► Artikel lesen
21.01.CALLIDITAS THERAPEUTICS: Calliditas Announces Full Enrollment of the Phase 3 NefIgArd Trial2
20.01.Calliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today's R&D Day360STOCKHOLM, Jan. 20, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX) (NASDAQ - CALT) today announced it will provide information on the near-term...
► Artikel lesen
20.01.CALLIDITAS THERAPEUTICS: Calliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today's R&D Day-
19.01.Calliditas Therapeutics AB - 6-K, Report of foreign issuer1
19.01.Calliditas/Genkyotex's setanaxib shows encouraging action in early-stage study1
18.01.CALLIDITAS THERAPEUTICS: Positive Phase 1 results in high-dose setanaxib trial-
15.01.Agenda for Calliditas virtual R&D Day on January 20, 2021199STOCKHOLM, Jan. 15, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX) (NASDAQ - CALT) today announced the program for the upcoming virtual R&D Day...
► Artikel lesen
Seite:  Weiter >>
78 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1